Heart Failure Industry, March 2015 Market Reports from Top Publishers

You might be interested in: medical equipment, chronic heart failure, therapeutics, telemedicine, angina, angina pectoris, cardiology, drug delivery, hospital, medical center, neurology, stem cell, stent, transdermal drug delivery.


 
1-10 of about 100 reports for Heart Failure

Physician Views: New data for Novartis% LCZ696 set the Street abuzz, but how do cardiologists see it fitting into highly genericised heart failure market?

Physician Views: New data for Novartis% LCZ696 set the Street abuzz, but how do cardiologists see it fitting into highly genericised heart failure market?

  • $ 645
  • Industry report
  • Mar 2015
  • by Firstword Pharma

The potential blockbuster status of Novartis' LCZ696 has seemingly been cemented in the eyes of the Street thanks to solid results from the Phase III PARADIGM-HF study that were presented over the weekend. ...

Congestive Heart Failure (Heart Failure)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Congestive Heart Failure (Heart Failure)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

  • $ 2 000
  • Industry report
  • February 2015
  • by Delve Insight

DelveInsight's, “Congestive Heart Failure (Heart Failure)-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs ...

Acute Heart Failure-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Acute Heart Failure-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

  • $ 2 000
  • Industry report
  • February 2015
  • by Delve Insight

DelveInsight's, “Acute Heart Failure-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs ...

Chronic Heart Failure-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

Chronic Heart Failure-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015

  • $ 2 000
  • Industry report
  • February 2015
  • by Delve Insight

DelveInsight's, “Chronic Heart Failure-Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2015”, Report provides comprehensive insights about phase III pipeline drugs and marketed drugs ...

Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2015

Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2015

  • $ 2 000
  • Industry report
  • January 2015
  • by Global Markets Direct

Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2015 Summary Global Markets Direct's, ‘Congestive Heart Failure (Heart Failure) - Pipeline Review, H1 2015', provides an overview of the ...

Global Congestive Heart Failure Drugs Market 2015-2019

Global Congestive Heart Failure Drugs Market 2015-2019

  • $ 3 000
  • Industry report
  • January 2015
  • by Infiniti Research Limited

About Congestive Heart Failure Drugs Congestive heart failure is a serious and complex condition in which the heart muscles are either damaged or have to work too hard. Although the heart beats, the damaged ...

Global Pharma US & EU Outlook 2015  : First -In- Class Innovations and Cost Optimization Plays Major Role In Shaping Up Business for Large Cap Pharmaceutical Companies

Global Pharma US & EU Outlook 2015 : First -In- Class Innovations and Cost Optimization Plays Major Role In Shaping Up Business for Large Cap Pharmaceutical Companies

  • $ 2 000
  • Industry report
  • January 2015
  • by MP Advisors

Strategy Diversification Divested: Productivity measurements, Divestment of non-core assets resulting in healthy Cash position- Will accelerate Next wave of targeted acquisition. In the recent years several ...

Mature Biotech  Outlook 2015: New Therapy Ventures Pave the Way for Success

Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success

  • $ 2 000
  • Industry report
  • January 2015
  • by MP Advisors

All biotech companies - Gilead (GILD), Amgen (AMGN), Biogen Idec (BIIB) and Celgene (CELG), in past year, have given a positive return and hence increased the interest of biotech investors. These companies ...

World Pathology: Acute Heart Failure – Pipeline Review, H1 2012

World Pathology: Acute Heart Failure – Pipeline Review, H1 2012

  • $ 2 000
  • Industry report
  • January 2015
  • by Global Markets Direct

This report provides data on the therapeutic development for Acute Heart Failure, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players ...

Pathology in United States: Iron Deficiency Anemia – Pipeline Review, H1 2012

Pathology in United States: Iron Deficiency Anemia – Pipeline Review, H1 2012

  • $ 2 000
  • Industry report
  • January 2015
  • by Global Markets Direct

This report provides data on the therapeutic development for Iron Deficiency Anemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players ...

About 2 700 reports for Heart Failure

Download Unlimited Documents from Trusted Public Sources

Hospital Industry in the US

  • September 2013
    89 pages
  • Hospital  

    Pneumonia  

    Heart Failure  

  • United States  

    North America  

View report >

4 Companies for Heart Failure

Read our Company Profiles

Bayer AG

Germany

Select Products Inc.

United States

Novartis Inc.

Switzerland

GlaxoSmithKline P.L.C.

United States

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.